

Asthma Treatment Pathway

Ages 6-11 (See page 2 for 12 + to Adult)




Box 3-5B. Personalized management for children 6–11 years to control symptoms and minimize future risk

Children 6-11 years

Personalized asthma management:

Assess, Adjust, Review



Asthma medication options:

Adjust treatment up and down for individual child's needs

PREFERRED CONTROLLER
to prevent exacerbations and control symptoms

Other controller options (limited indications, or less evidence for efficacy or safety)

RELIEVER

STEP 1
Low dose ICS taken whenever SABA taken

Consider daily low dose ICS

STEP 2
Daily low dose inhaled corticosteroid (ICS) (see table of ICS dose ranges for children)

Daily leukotriene receptor antagonist (LTRA), or low dose ICS taken whenever SABA taken

STEP 3
Low dose ICS-LABA, OR medium dose ICS, OR very low dose* ICS-formoterol maintenance and reliever therapy (MART). Refer for expert advice

Low dose ICS + LTRA

STEP 4
Medium dose ICS-LABA, OR low dose† ICS-formoterol maintenance and reliever therapy, e.g. anti-IgE, anti-IL4R

Add tiotropium or add LTRA

Add-on anti-IL5 or, as last resort, consider add-on low dose OCS, but consider side-effects

As-needed short-acting beta₂-agonist (or ICS-formoterol reliever for MART as above)

*Very low dose: BUD-FORM 100/6 mcg

†Low dose: BUD-FORM 200/6 mcg (metered doses).



OHP (Medicaid) Formulary Agents

Controller ICS:

- fluticasone HFA
- fluticasone Diskus
- Qvar (HFA)

ICS-LABA:

- Fluticasone/salmeterol [fluticasone/salmeterol Diskus (DPI), Wixela (DPI), fluticasone-salmeterol DPI]
- Advair HFA

ICS-formoterol (MART):

- Budesonide-formoterol [Budesonide-formoterol (HFA), Breyna (HFA)]

SABA:

- albuterol HFA
- levalbuterol HFA

Most pediatric members will have OHP. Spacers are covered on the formulary.

COA (Medicare) Formulary Agents

Controller ICS:

- Arnuity Ellipta (DPI)
- Qvar (HFA)
- Armonair Dihaler (DPI)

ICS-LABA:

- Fluticasone/salmeterol [fluticasone/salmeterol Diskus (DPI), Wixela (DPI), fluticasone-salmeterol DPI]
- Advair HFA
- Breo Ellipta (DPI)

ICS-formoterol (MART):

- Budesonide-formoterol [Breyna (HFA), budesonide-formoterol (HFA)]

SABA:

- albuterol HFA
- levalbuterol HFA

Spacers are covered on the Medicaid secondary benefit.

Asthma Treatment Pathway

Ages 12+ to Adult




Box 3-5A. Personalized management for adults and adolescents to control symptoms and minimize future risk

Adults & adolescents 12+ years

Personalized asthma management

Assess, Adjust, Review
for individual patient needs



GINA 2022, Box 3-5A

© Global Initiative for Asthma, www.ginasthma.org

GINA ©2023 Global Initiative for Asthma, reprinted with permission. Available from www.ginasthma.org; **Formulary subject to change**; Last updated 02/29/2024

SABA= short-acting beta agonist; LABA= long-acting beta agonist; ICS= inhaled corticosteroid; LAMA= long-acting muscarinic antagonist; MART= maintenance and reliever therapy

DPI = dry powder inhaler; HFA= hydrofluoroalkane (propellant) inhaler

OHP (Medicaid) Formulary Agents

Controller ICS:

- fluticasone HFA
- fluticasone Diskus (DPI)
- Qvar (HFA)

ICS-LABA:

- Fluticasone/salmeterol [fluticasone/salmeterol Diskus (DPI), Wixela (DPI), fluticasone-salmeterol DPI]
- Advair HFA

ICS-formoterol (MART):

- Budesonide-formoterol [Budesonide-formoterol (HFA), Breyna (HFA)]

LAMA:

- Spiriva Respimat (**PA required**)

ICS-LABA-LAMA:

- Trelegy Ellipta (DPI) (**PA required**)

SABA:

- albuterol HFA
- levalbuterol HFA

Most pediatric members will have OHP. Spacers are covered on the formulary.

COA (Medicare) Formulary Agents

Controller ICS:

- Arnuity Ellipta (DPI)
- Qvar (HFA)
- Armonair Digihaler (DPI)

ICS-LABA:

- Fluticasone/salmeterol [fluticasone/salmeterol Diskus (DPI), Wixela (DPI), fluticasone-salmeterol DPI]
- Advair HFA

ICS-formoterol (MART):

- Budesonide-formoterol [Breyna (HFA), budesonide-formoterol (HFA)]

LAMA:

- Spiriva Respimat

ICS-LABA-LAMA:

- Trelegy Ellipta (DPI) ([step therapy](#) required)

SABA:

- albuterol HFA
- levalbuterol HFA

Spacers are covered on the Medicaid secondary benefit.